Literature DB >> 19126406

Breast cancer cell response to genistein is conditioned by BRCA1 mutations.

Maud Privat1, Corinne Aubel, Stéphanie Arnould, Yves Communal, Marc Ferrara, Yves-Jean Bignon.   

Abstract

Soy phytoestrogens, among which genistein, seem to protect from breast cancer development. In order to study the role of the breast tumour suppressor BRCA1 in response to genistein, we used a new breast cancer cell model: the SUM1315MO2 cell line carrying the 185delAG BRCA1 mutation, which we stably transfected with a plasmid encoding wild-type BRCA1. We showed that growth of BRCA1 mutant cells was strongly inhibited by genistein whereas it only had a weak effect in cells expressing wild-type BRCA1 protein. BRCA1 mutant cells hypersensitivity could be linked to higher expression of ERbeta gene, which suggests that genistein may be an efficient inhibitor of cancer development in BRCA1 mutant breast cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19126406     DOI: 10.1016/j.bbrc.2008.12.151

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

Review 1.  ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches.

Authors:  Jin-Qiang Chen; Jose Russo
Journal:  Biochim Biophys Acta       Date:  2009-06-13

2.  Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines.

Authors:  Emmanuelle Mounetou; Frédérique Penault-Llorca; Clémence Dubois; Robin Dufour; Pierre Daumar; Corinne Aubel; Claire Szczepaniak; Christelle Blavignac; Mahchid Bamdad
Journal:  Oncotarget       Date:  2017-08-24

3.  A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors.

Authors:  Maud Privat; Amélie Cavard; Yanis Zekri; Flora Ponelle-Chachuat; Ioana Molnar; Nicolas Sonnier; Yves-Jean Bignon
Journal:  Int J Med Sci       Date:  2020-10-01       Impact factor: 3.738

4.  Genistein inhibition of topoisomerase IIalpha expression participated by Sp1 and Sp3 in HeLa cell.

Authors:  Najing Zhou; Yunli Yan; Wenling Li; Yanling Wang; Lifen Zheng; Shuo Han; Yongxin Yan; Yunzhi Li
Journal:  Int J Mol Sci       Date:  2009-07-22       Impact factor: 6.208

5.  MicroRNA-centric measurement improves functional enrichment analysis of co-expressed and differentially expressed microRNA clusters.

Authors:  Su Yeon Lee; Kyung-Ah Sohn; Ju Han Kim
Journal:  BMC Genomics       Date:  2012-12-13       Impact factor: 3.969

6.  BRCA1 induces major energetic metabolism reprogramming in breast cancer cells.

Authors:  Maud Privat; Nina Radosevic-Robin; Corinne Aubel; Anne Cayre; Frédérique Penault-Llorca; Geoffroy Marceau; Vincent Sapin; Yves-Jean Bignon; Daniel Morvan
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

7.  Antioxydation And Cell Migration Genes Are Identified as Potential Therapeutic Targets in Basal-Like and BRCA1 Mutated Breast Cancer Cell Lines.

Authors:  Maud Privat; Justine Rudewicz; Nicolas Sonnier; Christelle Tamisier; Flora Ponelle-Chachuat; Yves-Jean Bignon
Journal:  Int J Med Sci       Date:  2018-01-01       Impact factor: 3.738

8.  Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer.

Authors:  Abderrahim El Guerrab; Mahchid Bamdad; Fabrice Kwiatkowski; Yves-Jean Bignon; Frédérique Penault-Llorca; Corinne Aubel
Journal:  Oncotarget       Date:  2016-11-08

9.  Genistein Inhibits Proliferation of BRCA1 Mutated Breast Cancer Cells: The GPR30-Akt Axis as a Potential Target.

Authors:  Ga Yun Kim; Jinyoung Suh; Jeong-Hoon Jang; Do-Hee Kim; Ock Jin Park; Sue K Park; Young-Joon Surh
Journal:  J Cancer Prev       Date:  2019-12-30

Review 10.  Estrogen Actions in Triple-Negative Breast Cancer.

Authors:  Oliver Treeck; Susanne Schüler-Toprak; Olaf Ortmann
Journal:  Cells       Date:  2020-10-26       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.